Evidence map›Paper›PMID 28715426›Full record

SynthesisPLoS neglected tropical diseases2017

Community effectiveness of pyriproxyfen as a dengue vector control method: A systematic review.

Dorit Maoz, Tara Ward, Moody Samuel, Pie Müller, Silvia Runge-Ranzinger, Joao Toledo, Ross Boyce, Raman Velayudhan, Olaf Horstick

Abstract readSystematic Review
In one paragraph

Synthesis in PLoS neglected tropical diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Trial
  4. Acceptability of Integrated Vector Management ofTropical medicine and infectious disease · 2026
    Article
  5. Strategies forOne health (Amsterdam, Netherlands) · 2026
    Review
  6. The Effectiveness of Dengue Vector Control: A Meta-Review.Tropical medicine & international health : TM & IH · 2025
    Review
  7. Article
  8. Evidence map of strategies for preventing and controllingRevista panamericana de salud publica = Pan American journal of public health · 2025
    Review
  9. Review
  10. Article
  11. Article
  12. Pyriproxyfen Contamination inJournal of xenobiotics · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dorit MaozDepartment of Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland.
Tara WardPublic Health Specialist, Accra, Ghana.
Moody SamuelInstitute of Public Health, University of Heidelberg, Heidelberg, Germany.
Pie MüllerDepartment of Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland.
Silvia Runge-RanzingerInstitute of Public Health, University of Heidelberg, Heidelberg, Germany.
Joao ToledoPublic Health Specialist, Ministry of Health, Brasilia, Brazil.
Ross BoyceDivision of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Raman VelayudhanDepartment for the Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.
Olaf HorstickInstitute of Public Health, University of Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-9873-5686

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundVector control is the only widely utilised method for primary prevention and control of dengue. The use of pyriproxyfen may be promising, and autodissemination approach may reach hard to reach breeding places. It offers a unique mode of action (juvenile hormone mimic) and as an additional tool for the management of insecticide resistance among Aedes vectors. However, evidence of efficacy and community effectiveness (CE) remains limited.

objectiveThe aim of this systematic review is to compile and analyse the existing literature for evidence on the CE of pyriproxyfen as a vector control method for reducing Ae. aegypti and Ae. albopictus populations and thereby human dengue transmission.

methodsSystematic search of PubMed, Embase, Lilacs, Cochrane library, WHOLIS, Web of Science, Google Scholar as well as reference lists of all identified studies. Removal of duplicates, screening of abstracts and assessment for eligibility of the remaining studies followed. Relevant data were extracted, and a quality assessment conducted. Results were classified into four main categories of how pyriproxyfen was applied: - 1) container treatment, 2) fumigation, 3) auto-dissemination or 4) combination treatments,-and analysed with a view to their public health implication.

resultsOut of 745 studies 17 studies were identified that fulfilled all eligibility criteria. The results show that pyriproxyfen can be effective in reducing the numbers of Aedes spp. immatures with different methods of application when targeting their main breeding sites. However, the combination of pyriproxyfen with a second product increases efficacy and/or persistence of the intervention and may also slow down the development of insecticide resistance. Open questions concern concentration and frequency of application in the various treatments. Area-wide ultra-low volume treatment with pyriproxyfen currently lacks evidence and cannot be recommended. Community participation and acceptance has not consistently been successful and needs to be further assessed. While all studies measured entomological endpoints, only two studies measured the reduction in human dengue cases, with inconclusive results.

conclusionsAlthough pyriproxyfen is highly effective in controlling the immature stages of dengue transmitting mosquitoes, and-to a smaller degree-adult mosquitoes, there is weak evidence for a reduction of human dengue cases. More well designed larger studies with appropriate standardised outcome measures are needed before pyriproxyfen is incorporated in routine vector control programmes. Additionally, resistance to pyriproxyfen has been reported and needs investigation.

Indexed as

AedesAnimalsDengueDisease Transmission, InfectiousHealth Services ResearchHumansInsecticidesMosquito ControlMosquito VectorsPyridinesInsecticidesPyridinespyriproxyfen

Identifiers

PMID28715426
PMCPMC5531696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.